期刊
BRITISH JOURNAL OF CANCER
卷 99, 期 2, 页码 314-320出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6604472
关键词
prostate cancer; ETV1; ACSL3; ACSL3 : ETV1 fusion
类别
资金
- MRC [G0501019] Funding Source: UKRI
- Medical Research Council [G0501019] Funding Source: researchfish
- Cancer Research UK Funding Source: Medline
- Medical Research Council [G0501019] Funding Source: Medline
A fluorescence in situ hybridisation (FISH) assay has been used to screen for ETV1 gene rearrangements in a cohort of 429 prostate cancers from patients who had been diagnosed by trans-urethral resection of the prostate. The presence of ETV1 gene alterations (found in 23 cases, 5.4%) was correlated with higher Gleason Score (P = 0.001), PSA level at diagnosis (P = < 0.0001) and clinical stage (P = 0.017) but was not linked to poorer survival. We found that the six previously characterised translocation partners of ETV1 only accounted for 34% of ETV1 re-arrangements (eight out of 23) in this series, with fusion to the androgen-repressed gene C15orf21 representing the commonest event (four out of 23). In 5'-RACE experiments on RNA extracted from formalin-fixed tissue we identified the androgen-upregulated gene ACSL3 as a new 5'-translocation partner of ETV1. These studies report a novel fusion partner for ETV1 and highlight the considerable heterogeneity of ETV1 gene rearrangements in human prostate cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据